- Izotropic highlights recurrent challenges in current breast imaging technologies and the need for high-resolution, true 3D imaging
- The IzoView breast CT scan technology is created for accurate, compression-free imaging for women who have dense breast tissue
- Increased screening demands and regulatory momentum underscore the opportunities for dedicated breast CT solutions
- IZOZF’s innovative approaches highlight the company’s mission to improve diagnosis, detection, and care for people globally
Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device firm leading imaging-based solutions for better diagnosis, screening, and treatment of breast cancer patients, is bringing the challenges of current screening systems and the unique potential of the IzoView Breast CT Imaging solutions as part of efforts to mark Breast Cancer Awareness Month (ibn.fm/Hml57).
Breast cancer accounts for a third of cancer diagnoses among American women, making the need for better imaging solutions critical. Current solutions like tomosynthesis, mammography, and ultrasound are limited by tissue overlap, compression, and a high rate of false positives. These issues are quite…
NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at ibn.fm/IZOZF
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN